Prolia (Denosumab) Cost vs. Alternatives: A Class-by-Class Comparison

How Denosumab Works (and Why It Costs More Than a Pill)

Denosumab is a fully human monoclonal antibody that binds RANK ligand (RANKL), the protein signal osteoclasts need to mature, activate, and survive. By blocking RANKL, denosumab suppresses bone resorption at its source. This mechanism differs from bisphosphonates, which must first incorporate into bone mineral and then poison osteoclasts from the inside once they ingest that mineral 1.

Biologic vs. Small Molecule

That distinction matters for cost. Denosumab is a biologic drug manufactured in living cell lines, not a small molecule synthesized through standard chemistry. Biologic production requires mammalian cell culture, cold-chain storage, and sterile fill-finish. Generic alendronate, by contrast, is a chemical salt pressed into a tablet. The manufacturing gap alone explains a 15- to 50-fold price difference between the two.

Clinical Pharmacology in Brief

A single 60 mg subcutaneous dose suppresses serum C-telopeptide (CTX), a bone resorption marker, by approximately 85% within 3 days. The effect wears off by month 6, making the every-6-month dosing schedule pharmacologically required rather than arbitrary 2. Bisphosphonates, once embedded in bone, continue suppressing resorption for months to years after discontinuation. This pharmacokinetic difference has direct cost and safety implications that patients and prescribers should weigh together.

What Prolia Actually Costs in 2026

Wholesale acquisition cost (WAC) for a single Prolia 60 mg/mL prefilled syringe sits near $1,050 to $1,100. Two doses per year puts the annual WAC at roughly $2,100 to $2,200. Out-of-pocket costs depend entirely on coverage type.

Medicare Part B

Prolia administered in a physician's office is covered under Medicare Part B as a "physician-administered injectable." The standard patient share is 20% coinsurance after the Part B deductible ($240 in 2025), which translates to about $420 to $440 per year. Many Medigap or Medicare Advantage plans cover that coinsurance in full 3.

Commercial Insurance

Most commercial formularies list Prolia as a specialty drug on tier 3 or tier 4. Prior authorization is common and typically requires documentation that the patient either failed oral bisphosphonate therapy, has a contraindication (esophageal disorders, inability to remain upright 30 minutes), or has a T-score of −2.5 or below with additional fracture risk factors. Copays range from $50 to $500 per injection depending on plan design.

Amgen's Support Programs

Amgen offers the Prolia Patient Assistance Program for uninsured patients with household income below 300% of the federal poverty level. A separate copay card can reduce out-of-pocket cost to as low as $0 per injection for commercially insured patients, though Medicare beneficiaries are ineligible for copay cards by federal law.

Head-to-Head: Denosumab vs. Each Alternative

The osteoporosis pharmacopeia divides into antiresorptive agents (bisphosphonates, denosumab, selective estrogen receptor modulators) and anabolic agents (teriparatide, abaloparatide, romosozumab). Cost comparisons must account for efficacy, not just price.

Oral Bisphosphonates: Alendronate and Risedronate

Generic alendronate 70 mg weekly costs $2 to $10 per month at most retail pharmacies. Annual spend rarely exceeds $120. Risedronate 35 mg weekly is slightly more expensive at $15 to $30 per month for generic. The Fracture Intervention Trial (FIT) demonstrated that alendronate reduced vertebral fracture risk by 47% over 3 years in women with existing vertebral fractures 4. That is a strong result but falls short of the 68% vertebral fracture reduction observed with denosumab in FREEDOM (N=7,868) over the same duration 1.

The cost-per-fracture-prevented calculation favors bisphosphonates for moderate-risk patients. A 2017 analysis published in the Journal of Bone and Mineral Research estimated the incremental cost-effectiveness ratio (ICER) of denosumab versus generic alendronate at approximately $31,000 per quality-adjusted life year (QALY) in high-risk women aged 70 and older 5. That number falls below the commonly cited $50,000 to $100,000 per QALY threshold. For patients who truly cannot tolerate oral bisphosphonates, the higher price of denosumab is defensible.

IV Zoledronic Acid (Reclast)

Zoledronic acid 5 mg delivered as a once-yearly 15-minute intravenous infusion offers a middle ground. Annual cost ranges from $500 to $1,200 depending on infusion-center fees. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fractures over 3 years, statistically similar to the FREEDOM result for denosumab 6.

The AACE/ACE 2020 clinical practice guidelines state: "Zoledronic acid and denosumab are both appropriate first-line options for patients at high fracture risk who are unable to use oral bisphosphonates" 7. From a pure cost perspective, zoledronic acid is the more efficient choice when efficacy data are this close. The deciding clinical factors are renal function (zoledronic acid requires eGFR ≥35 mL/min; denosumab does not), needle phobia related to IV access, and the discontinuation rebound problem unique to denosumab.

Teriparatide (Forteo) and Abaloparatide (Tymlos)

Anabolic agents build new bone rather than simply slowing its loss. Teriparatide 20 mcg daily subcutaneous injection carries an annual cost of $3,200 to $4,500 for the branded Forteo pen. A generic teriparatide became available in 2024, bringing the annual cost closer to $2,400 to $3,000. Abaloparatide (Tymlos) costs approximately $2,500 to $3,500 per year.

The Endocrine Society's 2019 guideline recommends anabolic therapy as the initial treatment for patients at "very high fracture risk," defined as a recent vertebral fracture within 12 months, a T-score below −3.0, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% 8. Dr. Clifford Rosen, writing in the New England Journal of Medicine, noted: "Anabolic agents produce larger and faster gains in bone density than any antiresorptive, but they carry a time limitation: teriparatide use is capped at 24 months by the FDA label" 9.

After stopping teriparatide or abaloparatide, patients must transition to an antiresorptive agent (often denosumab or a bisphosphonate) to maintain the bone density gains. This sequential therapy model means the true lifetime cost of an anabolic-first approach includes both the anabolic phase ($5,000 to $9,000 over 2 years) and indefinite antiresorptive maintenance.

Romosozumab (Evenity)

Romosozumab, a sclerostin inhibitor with dual anabolic and antiresorptive action, is the most expensive option. Annual cost for the 12-month treatment course (210 mg SC monthly, administered as two 105 mg injections) ranges from $22,000 to $26,000. The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone and found a 48% lower risk of new vertebral fracture at 24 months with the sequential approach 10.

Romosozumab carries a boxed warning for cardiovascular risk (myocardial infarction and stroke), limiting its use to patients without recent cardiovascular events. For the subset of very-high-risk osteoporosis patients without cardiovascular contraindications, the short-term cost is steep but the fracture reduction data are compelling. Insurance coverage frequently requires step therapy through a bisphosphonate or denosumab first.

Raloxifene (Evista)

Raloxifene, a selective estrogen receptor modulator, costs $30 to $90 per year as a generic. It reduces vertebral fracture risk by 30% over 3 years in the MORE trial (N=7,705) but has shown no benefit for hip fracture prevention 11. The American Association of Clinical Endocrinology (AACE) positions raloxifene as an option for patients at moderate vertebral fracture risk who also want breast cancer risk reduction, not as a first-line agent for high-risk osteoporosis 7.

The Discontinuation Cost You Do Not See on the Invoice

Stopping denosumab creates a clinical problem that no other osteoporosis drug shares to the same degree. Within 12 to 18 months of the last injection, bone mineral density drops back to (or below) pre-treatment levels, and vertebral fracture risk spikes. The FREEDOM extension study documented multiple vertebral fractures in patients who discontinued after long-term use 12.

Transition Protocol Costs

Current consensus requires transitioning patients to a bisphosphonate (usually zoledronic acid) within 6 months of the last denosumab dose. This adds an infusion visit ($300 to $800), bone turnover marker labs ($50 to $150), and a follow-up DXA scan ($125 to $250). For patients who started denosumab assuming it would be a limited course, these transition costs are often unexpected.

The "Indefinite Therapy" Question

The 2020 AACE guidelines acknowledge: "Denosumab therapy is generally continued as long as the patient remains at high fracture risk, with the understanding that discontinuation requires a defined off-ramp" 7. Bisphosphonates allow drug holidays after 3 to 5 years because they remain embedded in bone. Denosumab does not. This pharmacologic reality means the cumulative lifetime cost of denosumab therapy is often higher than the annual WAC suggests.

Biosimilar Denosumab: When and How Much Cheaper

Amgen's composition-of-matter patent for denosumab expired in 2025. Several biosimilar manufacturers, including Sandoz, Samsung Bioepis, and Fresenius Kabi, have filed or received approval for denosumab biosimilars.

Expected Price Impact

Biosimilar competition in the U.S. Has historically reduced biologic prices by 20% to 40% within the first 2 years of market entry, based on patterns seen with filgrastim, infliximab, and adalimumab biosimilars 13. A 30% reduction in Prolia's WAC would bring annual cost to approximately $1,400 to $1,500, narrowing the gap with IV zoledronic acid but still well above oral generics.

Interchangeability and Formulary Shifts

The FDA's interchangeability designation allows pharmacy-level substitution without prescriber intervention. As biosimilars gain interchangeability status, insurers will likely move branded Prolia to non-preferred tiers or remove it from formularies entirely. Patients currently stable on Prolia should anticipate formulary notifications over the next 12 to 24 months.

Decision Framework: Matching the Drug to the Patient

Choosing an osteoporosis agent based on cost alone ignores the variables that determine real-world outcomes. The table below integrates cost, efficacy, and key clinical considerations.

| Agent | Annual Cost (est.) | Vertebral Fracture Reduction | Hip Fracture Reduction | Key Limitation | |---|---|---|---|---| | Alendronate (generic) | $20 to $120 | 47% (FIT) | 51% (FIT) | GI intolerance, esophageal risk | | Zoledronic acid (IV) | $500 to $1,200 | 70% (HORIZON) | 41% (HORIZON) | Requires eGFR ≥35 mL/min | | Denosumab (Prolia) | $1,800 to $2,200 | 68% (FREEDOM) | 40% (FREEDOM) | Rebound on discontinuation | | Teriparatide (generic) | $2,400 to $3,000 | 65% (Neer 2001) | Not powered | 24-month cap, daily injection | | Romosozumab (Evenity) | $22,000 to $26,000 | 73% (FRAME) | 38% (ARCH, vs. Alendronate) | CV boxed warning, 12-month limit | | Raloxifene (generic) | $30 to $90 | 30% (MORE) | No benefit shown | Vertebral only, VTE risk |

For patients with moderate fracture risk and no GI contraindications, generic alendronate remains the rational first-line choice. Patients who fail or cannot tolerate oral bisphosphonates should receive either IV zoledronic acid or denosumab, with the choice driven by renal function and willingness to commit to indefinite therapy. Anabolic agents are reserved for very high-risk patients and always followed by an antiresorptive consolidation phase.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research and Osteoporosis Center, has stated: "The optimal sequence is to start with the strongest agent the patient's risk profile warrants, then step down to maintenance antiresorptive therapy. Cost should inform but not dictate that sequencing" 14.

Insurance Navigation Tips

Patients facing high out-of-pocket costs for denosumab have several options worth exploring before accepting the sticker price.

Step Therapy Documentation

Most payers require documented bisphosphonate failure (adverse event, documented non-adherence due to GI effects, or fracture on therapy) before approving denosumab. Prescribers should include specific dates, adverse event descriptions, and DXA trends in prior authorization submissions.

Site of Service

Prolia administered in a hospital outpatient infusion center often costs more than the same injection in a physician's office due to facility fees. When possible, patients should request office-based administration.

State Pharmaceutical Assistance Programs

Seventeen states operate pharmaceutical assistance programs for residents who fall into coverage gaps. Eligibility and covered drugs vary, but several programs include injectable osteoporosis agents. The Medicare.gov State Pharmaceutical Assistance Programs page lists current options by state.

Patients with annual denosumab costs exceeding $2,000 out of pocket and a T-score at or above −2.5 at the hip should discuss switching to zoledronic acid with their clinician, provided renal function supports it (eGFR ≥35 mL/min per the label).